JPMorgan Chase & Co. Begins Coverage on TRex Bio (NASDAQ:TRXB)

Equities research analysts at JPMorgan Chase & Co. initiated coverage on shares of TRex Bio (NASDAQ:TRXB) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 46.63% from the stock’s current price.

Separately, Wedbush began coverage on TRex Bio in a research note on Monday. They issued an “outperform” rating and a $30.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $29.67.

TRex Bio Trading Down 0.7%

TRXB stock opened at $13.64 on Tuesday. TRex Bio has a 12-month low of $13.10 and a 12-month high of $16.56.

Insider Buying and Selling at TRex Bio

In other news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the company’s stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the purchase, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. This represents a 15.29% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.